- Home
- OCUL
as 08-01-2025 4:00pm EST
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.
Upcoming Earnings Alert:
Get ready for potential market movements as Ocular Therapeutix Inc. OCUL prepares to release earnings report on 05 Aug 2025.
| Founded: | 2006 | Country: | United States |
| Employees: | N/A | City: | BEDFORD |
| Market Cap: | 1.8B | IPO Year: | 2014 |
| Target Price: | $17.33 | AVG Volume (30 days): | 2.0M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.15 | EPS Growth: | N/A |
| 52 Week Low/High: | $5.79 - $12.35 | Next Earning Date: | 08-05-2025 |
| Revenue: | $59,647,000 | Revenue Growth: | -0.33% |
| Revenue Growth (this year): | -11.84% | Revenue Growth (next year): | 20.85% |
Stock Insider Trading Activity of Ocular Therapeutix Inc. (OCUL)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Waheed Nadia | OCUL | Chief Medical Officer | Jun 2 '25 | Sell | $8.05 | 13,861 | $111,581.05 | 206,805 | |
| Nayak Sanjay | OCUL | Chief Strategy Officer | May 23 '25 | Sell | $7.17 | 1,862 | $13,350.54 | 281,623 | |
| Dugel Pravin | OCUL | See Remarks | May 23 '25 | Sell | $7.18 | 21,219 | $152,352.42 | 3,499,099 | |
| Kaiser Peter | OCUL | Chief Development Officer | May 23 '25 | Sell | $7.17 | 2,974 | $21,323.58 | 207,104 | |
| Heier Jeffrey S. | OCUL | Chief Scientific Officer | May 23 '25 | Sell | $7.18 | 3,024 | $21,712.32 | 262,974 | |
| LINDSTROM RICHARD L MD | OCUL | Director | May 8 '25 | Buy | $6.96 | 10,000 | $69,600.00 | 172,704 |
Latest Ocular Therapeutix Inc. News
OCUL Breaking Stock News: Dive into OCUL Ticker-Specific Updates for Smart Investing
GlobeNewswire
a month ago
Ocular Therapeutix™ Unveils New Corporate Branding, Reflecting its Transformation to a Retina-Focused Company
Zacks
a month ago
Ocular Therapeutix (OCUL) Moves 8.6% Higher: Will This Strength Last?
Simply Wall St.
2 months ago
Ocular Therapeutix (NASDAQ:OCUL) shareholders have earned a 33% CAGR over the last three years
GlobeNewswire
2 months ago
Ocular Therapeutix™ to Participate in Clinical Trials at the Summit (CTS) 2025
MT Newswires
2 months ago
Sector Update: Health Care
MT Newswires
2 months ago
Ocular Shares Rise After Eye Disease Trial Nears Enrollment Completion
GlobeNewswire
2 months ago
Ocular Therapeutix™ To Close Enrollment This Week for SOL-R, its Second Registrational Trial Evaluating AXPAXLI™ in Wet Age-Related Macular Degeneration
GlobeNewswire
3 months ago
Ocular Therapeutix™ to Participate in Upcoming Investor Conferences
Compare OCUL vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "OCUL Ocular Therapeutix Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.